p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

Bioorg Med Chem Lett. 2001 Jan 8;11(1):9-12. doi: 10.1016/s0960-894x(00)00574-6.

Abstract

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.

MeSH terms

  • Arthritis / drug therapy*
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use*
  • Furans / chemical synthesis
  • Furans / chemistry
  • Furans / pharmacology
  • Furans / therapeutic use
  • Humans
  • Inhibitory Concentration 50
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / metabolism
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Molecular Structure
  • Osteoporosis / drug therapy*
  • Pyrroles / chemical synthesis
  • Pyrroles / chemistry
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Thiophenes / chemical synthesis
  • Thiophenes / chemistry
  • Thiophenes / pharmacology
  • Thiophenes / therapeutic use
  • Tumor Cells, Cultured
  • Urea / analogs & derivatives*
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Enzyme Inhibitors
  • Furans
  • Interleukin-6
  • Pyrroles
  • Thiophenes
  • Urea
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases